{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:09:29Z","timestamp":1792786169634,"version":"4.5.0"},"reference-count":115,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"EU","award":["825392"],"award-info":[{"award-number":["825392"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:p>\n                    Regulatory T cells (Treg), a subset of CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells, are potent regulators of immune reactions, which have been shown to be a promising therapeutic alternative to toxic immunosuppressive drugs. Data support the utility of Treg in managing immunopathologies, including solid organ transplant rejection, graft-versus-host disease, and autoimmune disorders. Notably, reports suggest that interleukin-2 (IL-2) is critical to survival of Treg, which constitutively express high levels of CD25, that is, the IL-2 receptor \u03b1-chain, and are exquisitely sensitive to IL-2, even at very low concentrations in contrast to effector T cells, which only upregulate IL-2 receptor \u03b1-chain on activation. This has led to the notion of using low doses of exogenous IL-2 therapeutically to modulate the immune system, specifically Treg numbers and function. Here, we summarize developments of clinical experience with low-dose IL-2 (LD-IL-2) as a therapeutic agent. So far, no clinical data are available to support the therapeutic use of LD-IL-2 therapy in the solid organ transplant setting. For the latter, fine-tuning by biotechnological approaches may be needed because of the narrow therapeutic window and off-target effects of LD-IL-2 therapy and so to realize the therapeutic potential of this molecule.\n                  <\/jats:p>","DOI":"10.1097\/tp.0000000000004866","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T12:00:14Z","timestamp":1706702414000},"page":"1492-1508","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Low-dose Interleukin-2 Therapy: Fine-tuning Treg in Solid Organ Transplantation?"],"prefix":"10.1097","volume":"108","author":[{"given":"Leila","family":"Amini","sequence":"first","affiliation":[{"name":"Berlin Center for Advanced Therapies, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany."},{"name":"Berlin Institute of Health \u2013 Center for Regenerative Therapies, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaspal","family":"Kaeda","sequence":"additional","affiliation":[{"name":"Berlin Center for Advanced Therapies, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Weber","sequence":"additional","affiliation":[{"name":"Institute of Molecular Medicine and Experimental Immunology (IMMEI), University of Bonn, Bonn, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Reinke","sequence":"additional","affiliation":[{"name":"Berlin Center for Advanced Therapies, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany."},{"name":"Berlin Institute of Health \u2013 Center for Regenerative Therapies, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"R1-20250604","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1202947","article-title":"Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4.","volume":"332","author":"Qureshi","year":"2011","journal-title":"Science"},{"key":"R2-20250604","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41590-018-0280-2","article-title":"Regulatory T cells mediate specific suppression by depleting peptide-MHC class II from dendritic cells.","volume":"20","author":"Akkaya","year":"2019","journal-title":"Nat Immunol"},{"key":"R3-20250604","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/15256","article-title":"Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance.","volume":"5","author":"Li","year":"1999","journal-title":"Nat Med"},{"key":"R4-20250604","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1182\/blood-2006-01-0329","article-title":"Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production.","volume":"108","author":"Zeiser","year":"2006","journal-title":"Blood"},{"key":"R5-20250604","doi-asserted-by":"crossref","first-page":"7083","DOI":"10.1073\/pnas.1620835114","article-title":"IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors.","volume":"114","author":"Whitehouse","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R6-20250604","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.transproceed.2006.08.081","article-title":"Calcineurin inhibitors affect circulating regulatory T cells in stable renal transplant recipients.","volume":"38","author":"San Segundo","year":"2006","journal-title":"Transplant Proc"},{"key":"R7-20250604","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ki.2009.198","article-title":"Differential kinetics of effector and regulatory T cells in patients on calcineurin inhibitor-based drug regimens.","volume":"76","author":"Presser","year":"2009","journal-title":"Kidney Int"},{"key":"R8-20250604","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1182\/blood-2009-10-233585","article-title":"NFAT pulls the strings during CD4+ T helper cell effector functions.","volume":"115","author":"Hermann-Kleiter","year":"2010","journal-title":"Blood"},{"key":"R9-20250604","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3389\/fimmu.2017.00219","article-title":"Methylation of FOXP3 TSDR underlies the impaired suppressive function of Tregs from long-term belatacept-treated kidney transplant patients.","volume":"8","author":"Alvarez Salazar","year":"2017","journal-title":"Front Immunol"},{"key":"R10-20250604","doi-asserted-by":"crossref","first-page":"3449","DOI":"10.1111\/j.1600-6143.2012.04269.x","article-title":"Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients.","volume":"12","author":"Akimova","year":"2012","journal-title":"Am J Transplant"},{"key":"R11-20250604","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/ajt.13617","article-title":"Hepatic infiltrates in operational tolerant patients after liver transplantation show enrichment of regulatory T cells before proinflammatory genes are downregulated.","volume":"16","author":"Taubert","year":"2016","journal-title":"Am J Transplant"},{"key":"R12-20250604","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1172\/JCI41072","article-title":"Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation.","volume":"120","author":"Matsuoka","year":"2010","journal-title":"J Clin Invest"},{"key":"R13-20250604","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3324\/haematol.2014.104166","article-title":"Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation.","volume":"99","author":"Murase","year":"2014","journal-title":"Haematologica"},{"key":"R14-20250604","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1182\/blood-2011-06-362137","article-title":"Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation.","volume":"118","author":"Kawano","year":"2011","journal-title":"Blood"},{"key":"R15-20250604","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/scitranslmed.3005265","article-title":"Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease.","volume":"5","author":"Matsuoka","year":"2013","journal-title":"Sci Transl Med"},{"key":"R16-20250604","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/CJI.0b013e3181cd870f","article-title":"Increase of circulating CD4+CD25highFoxP3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2.","volume":"33","author":"Berntsen","year":"2010","journal-title":"J Immunother"},{"key":"R17-20250604","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jaci.2006.10.007","article-title":"CD25 deficiency causes an immune dysregulation, polyendocrinopathy, enteropathy, X-linked-like syndrome, and defective IL-10 expression from CD4 lymphocytes.","volume":"119","author":"Caudy","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"R18-20250604","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1073\/pnas.94.7.3168","article-title":"Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor.","volume":"94","author":"Sharfe","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R19-20250604","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","article-title":"Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus.","volume":"75","author":"von Spee-Mayer","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R20-20250604","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jaci.2010.05.022","article-title":"Inducible costimulator (ICOS) is a marker for highly suppressive antigen-specific T cells sharing features of TH17\/TH1 and regulatory T cells.","volume":"126","author":"Vocanson","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"R21-20250604","doi-asserted-by":"crossref","first-page":"e89278","DOI":"10.1172\/jci.insight.89278","article-title":"Low-dose IL-2 selectively activates subsets of CD4(+) Tregs and NK cells.","volume":"1","author":"Hirakawa","year":"2016","journal-title":"JCI Insight"},{"key":"R22-20250604","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.2337\/db14-1322","article-title":"Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes.","volume":"64","author":"Yu","year":"2015","journal-title":"Diabetes"},{"key":"R23-20250604","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/eji.202149318","article-title":"Helios is a marker, not a driver, of human Treg stability.","volume":"52","author":"Lam","year":"2022","journal-title":"Eur J Immunol"},{"key":"R24-20250604","doi-asserted-by":"crossref","first-page":"11906","DOI":"10.1073\/pnas.1002569107","article-title":"Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells.","volume":"107","author":"Krieg","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R25-20250604","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ajt.2023.01.016","article-title":"Low-dose interleukin-2 promotes immune regulation in face transplantation: a pilot study.","volume":"23","author":"Murakami","year":"2023","journal-title":"Am J Transplant"},{"key":"R26-20250604","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1126\/science.1122927","article-title":"Selective stimulation of T cell subsets with antibody-cytokine immune complexes.","volume":"311","author":"Boyman","year":"2006","journal-title":"Science"},{"key":"R27-20250604","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.kint.2016.09.022","article-title":"IL-2\/anti-IL-2 complexes ameliorate lupus nephritis by expansion of CD4(+)CD25(+)Foxp3(+) regulatory T cells.","volume":"91","author":"Yan","year":"2017","journal-title":"Kidney Int"},{"key":"R28-20250604","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1182\/blood.V120.21.3283.3283","article-title":"Ultra-low dose IL-2 safely expands regulatory T cells and CD56bright NK cells in healthy volunteers: towards safer stem cell donors?","volume":"120","author":"Ito","year":"2012","journal-title":"Blood"},{"key":"R29-20250604","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/mt.2014.50","article-title":"Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers.","volume":"22","author":"Ito","year":"2014","journal-title":"Mol Ther"},{"key":"R30-20250604","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1182\/blood-2006-02-004747","article-title":"IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo.","volume":"108","author":"Zorn","year":"2006","journal-title":"Blood"},{"key":"R31-20250604","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1056\/NEJMoa1105143","article-title":"Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.","volume":"365","author":"Saadoun","year":"2011","journal-title":"N Engl J Med"},{"key":"R32-20250604","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/(SICI)1096-9071(199803)54:3<167::AID-JMV4>3.0.CO;2-3","article-title":"Double-blind, randomized controlled trial of interleukin-2 treatment of chronic hepatitis B.","volume":"54","author":"Artillo","year":"1998","journal-title":"J Med Virol"},{"key":"R33-20250604","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hep.1840080309","article-title":"Pilot study of recombinant human interleukin 2 for chronic type B hepatitis.","volume":"8","author":"Kakumu","year":"1988","journal-title":"Hepatology"},{"key":"R34-20250604","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0168-8278(05)80580-X","article-title":"Pilot study of natural human interleukin-2 in patients with chronic hepatitis B.","volume":"19","author":"Tilg","year":"1993","journal-title":"J Hepatol"},{"key":"R35-20250604","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-8587(13)70113-X","article-title":"Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1\/2 randomised, double-blind, placebo-controlled trial.","volume":"1","author":"Hartemann","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R36-20250604","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","article-title":"Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients.","volume":"58","author":"Rosenzwajg","year":"2015","journal-title":"J Autoimmun"},{"key":"R37-20250604","doi-asserted-by":"crossref","first-page":"e1002139","DOI":"10.1371\/journal.pmed.1002139","article-title":"Regulatory T cell responses in participants with type 1 diabetes after a single dose of interleukin-2: a non-randomised, open label, adaptive dose-finding trial.","volume":"13","author":"Todd","year":"2016","journal-title":"PLoS Med"},{"key":"R38-20250604","doi-asserted-by":"crossref","first-page":"e005559","DOI":"10.1136\/bmjopen-2014-005559","article-title":"Rationale and study design of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D): a non-randomised, open label, adaptive dose finding trial.","volume":"4","author":"Waldron-Lynch","year":"2014","journal-title":"BMJ Open"},{"key":"R39-20250604","doi-asserted-by":"crossref","first-page":"e99306","DOI":"10.1172\/jci.insight.99306","article-title":"The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes.","volume":"3","author":"Seelig","year":"2018","journal-title":"JCI Insight"},{"key":"R40-20250604","doi-asserted-by":"crossref","first-page":"e009799","DOI":"10.1136\/bmjopen-2015-009799","article-title":"Protocol of the adaptive study of IL-2 dose frequency on regulatory T cells in type 1 diabetes (DILfrequency): a mechanistic, non-randomised, repeat dose, open-label, response-adaptive study.","volume":"5","author":"Truman","year":"2015","journal-title":"BMJ Open"},{"key":"R41-20250604","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/annrheumdis-2014-206506","article-title":"Rapid induction of clinical remission by low-dose interleukin-2 in a patient with refractory SLE.","volume":"74","author":"Humrich","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R42-20250604","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nm.4148","article-title":"Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus.","volume":"22","author":"He","year":"2016","journal-title":"Nat Med"},{"key":"R43-20250604","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial.","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R44-20250604","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1136\/ard-2022-222501","article-title":"Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial.","volume":"81","author":"Humrich","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R45-20250604","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1001\/jamadermatol.2014.504","article-title":"Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata.","volume":"150","author":"Castela","year":"2014","journal-title":"JAMA Dermatol"},{"key":"R46-20250604","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1002\/hep.30059","article-title":"Low-dose interleukin-2 for refractory autoimmune hepatitis.","volume":"68","author":"Lim","year":"2018","journal-title":"Hepatology"},{"key":"R47-20250604","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1136\/annrheumdis-2019-216246","article-title":"Circulating regulatory T cells were absolutely decreased in dermatomyositis\/polymyositis patients and restored by low-dose IL-2.","volume":"80","author":"Zhang","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"R48-20250604","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/annrheumdis-2018-213036","article-title":"Short-term and low-dose IL-2 therapy restores the Th17\/Treg balance in the peripheral blood of patients with primary Sjogren\u2019s syndrome.","volume":"77","author":"Miao","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R49-20250604","doi-asserted-by":"crossref","first-page":"2040622320916014","DOI":"10.1177\/2040622320916014","article-title":"The numbers of peripheral regulatory T cells are reduced in patients with psoriatic arthritis and are restored by low-dose interleukin-2.","volume":"11","author":"Wang","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"key":"R50-20250604","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1053\/j.gastro.2021.01.053","article-title":"Low dose Il-2 for the treatment of moderate to severe ulcerative colitis.","volume":"160","author":"Allegretti","year":"2021","journal-title":"Gastroenterology"},{"key":"R51-20250604","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R52-20250604","doi-asserted-by":"crossref","first-page":"102844","DOI":"10.1016\/j.ebiom.2020.102844","article-title":"Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): a phase 2a randomised, double-blind, placebo-controlled trial.","volume":"59","author":"Camu","year":"2020","journal-title":"EBioMedicine"},{"key":"R53-20250604","doi-asserted-by":"crossref","first-page":"e022452","DOI":"10.1136\/bmjopen-2018-022452","article-title":"Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind, placebo-controlled, phase I\/II clinical trial.","volume":"8","author":"Zhao","year":"2018","journal-title":"BMJ Open"},{"key":"R54-20250604","doi-asserted-by":"crossref","first-page":"ehaa946.1735","DOI":"10.1093\/ehjci\/ehaa946.1735","article-title":"Low dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndrome (LILACS).","volume":"41","author":"Zhao","year":"2020","journal-title":"Eur Heart J"},{"key":"R55-20250604","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2100009","article-title":"Regulatory T-cell response to low-dose interleukin-2 in ischemic heart disease.","volume":"1","author":"Zhao","year":"2022","journal-title":"NEJM Evidence"},{"key":"R56-20250604","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1097\/00002371-200409000-00006","article-title":"Assessment of the toxicities of systemic low-dose interleukin-2 administered in conjunction with a melanoma peptide vaccine.","volume":"27","author":"Woodson","year":"2004","journal-title":"J Immunother"},{"key":"R57-20250604","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1097\/TP.0b013e3181a2dee6","article-title":"Acute liver transplant rejection upon immunosuppression withdrawal in a tolerance induction trial: potential role of IFN-gamma-secreting CD8+ T cells.","volume":"87","author":"Donckier","year":"2009","journal-title":"Transplantation"},{"key":"R58-20250604","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1182\/blood-2003-07-2598","article-title":"CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis.","volume":"103","author":"Boyer","year":"2004","journal-title":"Blood"},{"key":"R59-20250604","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1002\/art.23759","article-title":"Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis.","volume":"58","author":"Landau","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R60-20250604","first-page":"2","article-title":"Low-dose IL-2 therapy for autoimmune diseases.","volume":"15","author":"Collison","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"R61-20250604","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1161\/ATVBAHA.112.251579","article-title":"Low levels of circulating CD4+FoxP3+ T cells are associated with an increased risk for development of myocardial infarction but not for stroke.","volume":"32","author":"Wigren","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R62-20250604","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood.V79.2.517.517","article-title":"Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation.","volume":"79","author":"Soiffer","year":"1992","journal-title":"Blood"},{"key":"R63-20250604","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2249.1992.tb03025.x","article-title":"IL-2 infusion abrogates humoral immune responses in humans.","volume":"87","author":"Gottlieb","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"R64-20250604","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood.V84.3.964.964","article-title":"Effect of low-dose interleukin-2 on disease relapse after T-cell- depleted allogeneic bone marrow transplantation.","volume":"84","author":"Soiffer","year":"1994","journal-title":"Blood"},{"key":"R65-20250604","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/sj.bmt.1700693","article-title":"Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non-randomized study.","volume":"19","author":"Lopez-Jimenez","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"R66-20250604","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease.","volume":"365","author":"Koreth","year":"2011","journal-title":"N Engl J Med"},{"key":"R67-20250604","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1182\/blood-2016-02-702852","article-title":"Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.","volume":"128","author":"Koreth","year":"2016","journal-title":"Blood"},{"key":"R68-20250604","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1182\/bloodadvances.2018027474","article-title":"Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease.","volume":"3","author":"Whangbo","year":"2019","journal-title":"Blood Adv"},{"key":"R69-20250604","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/1078-0432.CCR-13-3205","article-title":"Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.","volume":"20","author":"Kennedy-Nasser","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R70-20250604","doi-asserted-by":"crossref","first-page":"e1250992","DOI":"10.1080\/2162402X.2016.1250992","article-title":"Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: a randomized study.","volume":"5","author":"Zhao","year":"2016","journal-title":"Oncoimmunology"},{"key":"R71-20250604","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1182\/bloodadvances.2019000631","article-title":"Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children.","volume":"3","author":"Whangbo","year":"2019","journal-title":"Blood Adv"},{"key":"R72-20250604","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1182\/bloodadvances.2022007773","article-title":"Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease.","volume":"6","author":"Kim","year":"2022","journal-title":"Blood Adv"},{"key":"R73-20250604","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1084\/jem.20082824","article-title":"In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression.","volume":"206","author":"Webster","year":"2009","journal-title":"J Exp Med"},{"key":"R74-20250604","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2337\/db19-0525","article-title":"Low-dose interleukin-2 combined with rapamycin led to an expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells and prolonged human islet allograft survival in humanized mice.","volume":"69","author":"Hu","year":"2020","journal-title":"Diabetes"},{"key":"R75-20250604","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/TP.0000000000001044","article-title":"In vivo expansion of regulatory T cells by low-dose interleukin-2 treatment increases allograft survival in corneal transplantation.","volume":"100","author":"Tahvildari","year":"2016","journal-title":"Transplantation"},{"key":"R76-20250604","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1111\/ajt.17101","article-title":"Low-dose IL-2 prevents murine chronic cardiac allograft rejection: role for IL-2-induced T regulatory cells and exosomes with PD-L1 and CD73.","volume":"22","author":"Ravichandran","year":"2022","journal-title":"Am J Transplant"},{"key":"R77-20250604","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1111\/ajt.13382","article-title":"Repeated injections of IL-2 break renal allograft tolerance induced via mixed hematopoietic chimerism in monkeys.","volume":"15","author":"Yamada","year":"2015","journal-title":"Am J Transplant"},{"key":"R78-20250604","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2022.08.035","article-title":"Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote liver allograft tolerance in humans.","volume":"78","author":"Lim","year":"2023","journal-title":"J Hepatol"},{"key":"R79-20250604","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1182\/bloodadvances.2018029124","article-title":"Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease.","volume":"3","author":"Belizaire","year":"2019","journal-title":"Blood Adv"},{"key":"R80-20250604","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12865-019-0305-0","article-title":"Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17\/Treg cells in refractory SLE patients.","volume":"20","author":"Zhao","year":"2019","journal-title":"BMC Immunol"},{"key":"R81-20250604","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.1182\/bloodadvances.2021006625","article-title":"A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.","volume":"6","author":"Whangbo","year":"2022","journal-title":"Blood Adv"},{"key":"R82-20250604","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jcyt.2014.11.005","article-title":"Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease.","volume":"17","author":"Theil","year":"2015","journal-title":"Cytotherapy"},{"key":"R83-20250604","doi-asserted-by":"crossref","first-page":"e147474","DOI":"10.1172\/jci.insight.147474","article-title":"The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes.","volume":"6","author":"Dong","year":"2021","journal-title":"JCI Insight"},{"key":"R84-20250604","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1086\/314831","article-title":"Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with \u2264250\/\u00b5L CD4 T cells and undetectable plasma virus load.","volume":"180","author":"Arno","year":"1999","journal-title":"J Infect Dis"},{"key":"R85-20250604","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2249.2000.01223.x","article-title":"Decreased CD95 expression on naive T cells from HIV-infected persons undergoing highly active anti-retroviral therapy (HAART) and the influence of IL-2 low dose administration.","volume":"120","author":"Amendola","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"R86-20250604","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1310\/T5FR-8JPX-0NEF-XDKD","article-title":"Low-dose daily subcutaneous interleukin-2 in combination with highly active antiretroviral therapy in HIV+ patients: a randomized controlled trial.","volume":"1","author":"Lalezari","year":"2000","journal-title":"HIV Clin Trials"},{"key":"R87-20250604","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/00126334-200405010-00005","article-title":"Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).","volume":"36","author":"Vogler","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R88-20250604","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/S0168-8278(05)80424-6","article-title":"Treatment of chronic hepatitis B with interferon \u03b1-2b and interleukin-2.","volume":"17","author":"Bruch","year":"1993","journal-title":"J Hepatol"},{"key":"R89-20250604","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1164\/rccm.200211-1359OC","article-title":"Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis.","volume":"168","author":"Johnson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"R90-20250604","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/sj.bmt.1703687","article-title":"Administration of low-dose interleukin-2 plus G-CSF\/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer.","volume":"30","author":"Perillo","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"R91-20250604","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1097\/QAI.0000000000000092","article-title":"HIV infection deregulates the balance between regulatory T cells and IL-2-producing CD4 T cells by decreasing the expression of the IL-2 receptor in Treg.","volume":"65","author":"Mendez-Lagares","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R92-20250604","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/infdis\/167.2.291","article-title":"Efficacy of low doses of the polyethylene glycol derivative of interleukin-2 in modulating the immune response of patients with human immunodeficiency virus type 1 infection.","volume":"167","author":"Teppler","year":"1993","journal-title":"J Infect Dis"},{"key":"R93-20250604","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1084\/jem.177.2.483","article-title":"Prolonged immunostimulatory effect of low-dose polyethylene glycol interleukin 2 in patients with human immunodeficiency virus type 1 infection.","volume":"177","author":"Teppler","year":"1993","journal-title":"J Exp Med"},{"key":"R94-20250604","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/annrheumdis-2019-eular.3395","article-title":"OP0195 Selective expansion of regulatory T-cells in humans by a novel IL-2 conjugate T-reg stimulator, NKTR-358, being developed for the treatment of autoimmune diseases.","volume":"78","author":"Fanton","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R95-20250604","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/blood.V130.Suppl_1.696.696","article-title":"Amg 592 Is an investigational IL-2 mutein that induces highly selective expansion of regulatory T cells.","volume":"130","author":"Tchao","year":"2017","journal-title":"Blood"},{"key":"R96-20250604","doi-asserted-by":"crossref","first-page":"1343.3","DOI":"10.1136\/annrheumdis-2022-eular.2244","article-title":"Ab0432 Efavaleukin alfa, a novel Il-2 mutein, selectively expands regulatory T cells in patients with SLE: final results of a phase 1b multiple ascending dose study.","volume":"81","author":"Tchao","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"R97-20250604","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/clpt.1991.33","article-title":"A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2.","volume":"49","author":"Meyers","year":"1991","journal-title":"Clin Pharmacol Ther"},{"key":"R98-20250604","doi-asserted-by":"crossref","first-page":"100103","DOI":"10.1016\/j.jtauto.2021.100103","article-title":"NKTR-358: a novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases.","volume":"4","author":"Dixit","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"R99-20250604","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2014.10.002","article-title":"Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells.","volume":"56","author":"Bell","year":"2015","journal-title":"J Autoimmun"},{"key":"R100-20250604","doi-asserted-by":"crossref","first-page":"e1009858","DOI":"10.1371\/journal.ppat.1009858","article-title":"Low-dose IL-2 therapy invigorates CD8+ T cells for viral control in systemic lupus erythematosus.","volume":"17","author":"Zhou","year":"2021","journal-title":"PLoS Pathog"},{"key":"R101-20250604","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2018.10.017","article-title":"A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.","volume":"95","author":"Peterson","year":"2018","journal-title":"J Autoimmun"},{"key":"R102-20250604","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41591-018-0070-2","article-title":"A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism.","volume":"24","author":"Trotta","year":"2018","journal-title":"Nat Med"},{"key":"R103-20250604","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.3389\/fimmu.2019.01877","article-title":"Specialized roles of human natural killer cell subsets in kidney transplant rejection.","volume":"10","author":"Kildey","year":"2019","journal-title":"Front Immunol"},{"key":"R104-20250604","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.kint.2018.08.027","article-title":"Natural killer cell infiltration is discriminative for antibody-mediated rejection and predicts outcome after kidney transplantation.","volume":"95","author":"Yazdani","year":"2019","journal-title":"Kidney Int"},{"key":"R105-20250604","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1002\/hep.26426","article-title":"Prospective multicenter clinical trial of immunosuppressive drug withdrawal in stable adult liver transplant recipients.","volume":"58","author":"Benitez","year":"2013","journal-title":"Hepatology"},{"key":"R106-20250604","doi-asserted-by":"crossref","first-page":"7428","DOI":"10.1038\/s41598-018-25574-7","article-title":"A phase I clinical trial with ex vivo expanded recipient regulatory T cells in living donor kidney transplants.","volume":"8","author":"Mathew","year":"2018","journal-title":"Sci Rep"},{"key":"R107-20250604","doi-asserted-by":"crossref","first-page":"m3734","DOI":"10.1136\/bmj.m3734","article-title":"Regulatory T cells for minimising immune suppression in kidney transplantation: phase I\/IIa clinical trial.","volume":"371","author":"Roemhild","year":"2020","journal-title":"BMJ"},{"key":"R108-20250604","doi-asserted-by":"crossref","first-page":"eabo2628","DOI":"10.1126\/scitranslmed.abo2628","article-title":"Autologous donor-alloantigen reactive Treg cell therapy for minimization of immunosuppression after liver transplantation.","volume":"14","author":"Tang","year":"2022","journal-title":"Sci Transl Med"},{"key":"R109-20250604","doi-asserted-by":"crossref","first-page":"611638","DOI":"10.3389\/fimmu.2020.611638","article-title":"Super-Treg: toward a new era of adoptive Treg therapy enabled by genetic modifications.","volume":"11","author":"Amini","year":"2021","journal-title":"Front Immunol"},{"key":"R110-20250604","doi-asserted-by":"crossref","first-page":"7676","DOI":"10.1038\/s41598-021-87102-4","article-title":"Life-extended glycosylated IL-2 promotes Treg induction and suppression of autoimmunity.","volume":"11","author":"Ottolenghi","year":"2021","journal-title":"Sci Rep"},{"key":"R111-20250604","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1111\/ajt.14415","article-title":"Polyclonal regulatory T cell therapy for control of inflammation in kidney transplants.","volume":"17","author":"Chandran","year":"2017","journal-title":"Am J Transplant"},{"key":"R112-20250604","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1479-5876-7-89","article-title":"Human T cells express CD25 and Foxp3 upon activation and exhibit effector\/memory phenotypes without any regulatory\/suppressor function.","volume":"7","author":"Kmieciak","year":"2009","journal-title":"J Transl Med"},{"key":"R113-20250604","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/eji.200636435","article-title":"Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells.","volume":"37","author":"Wang","year":"2007","journal-title":"Eur J Immunol"},{"key":"R114-20250604","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.clim.2006.10.014","article-title":"Transient regulatory T-cells: a state attained by all activated human T-cells.","volume":"123","author":"Pillai","year":"2007","journal-title":"Clin Immunol"},{"key":"R115-20250604","doi-asserted-by":"crossref","first-page":"110110","DOI":"10.1097\/01.TP.0000164142.98167.4B","article-title":"Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells.","volume":"80","author":"Baan","year":"2005","journal-title":"Transplantation"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004866","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T14:06:20Z","timestamp":1749045980000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000004866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":115,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000004866","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,31]]}}}